A Global Test of Hemostatic Risk

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41HL076904-01
Agency Tracking Number: HL076904
Amount: $99,039.00
Phase: Phase I
Program: STTR
Awards Year: 2004
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
HAEMATOLOGIC TECHNOLOGIES, INC.
HAEMATOLOGIC TECHNOLOGIES, INC., 57 RIVER RD, ESSEX JUNCTION, VT, 05452
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RICHARD JENNY
 (802) 878-1777
 RJENNY@HAEMTECH.NET
Business Contact
 RICHARD JENNY
Phone: (802) 878-1777
Email: RJENNY@HAEMTECH.NET
Research Institution
 UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
 85 SOUTH PROSPECT STREET
BURLINGTON, VT, 05405
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Although the vast majority of patients who suffer from venous or arterial thrombosis have haemostatic systems that fall within the "normal" range of routine screening tools such as PT, aPTT, and factor assays, thrombosis is the major cause of death in Western countries. In contrast, the propensity to bleed (i.e., hemophilia) is more easily diagnosed by traditional assay methodology yet the extent of the pathology and the clinical management of these individuals is not accurately portrayed by these same assays. Para vivo models of blood coagulation developed at the University of Vermont have clearly demonstrated a correlation between an individual's potential to generate thrombin and several haemostatic defects. The assay system utilized in these studies is based on a tissue factor initiated whole blood clotting technique in which thrombin generation is monitored via quantitation of thrombin-antithrombin m complex formation. We propose to modify and make clinically accessible this existing comprehensive method of monitoring the haemostatic competence of whole blood. In phase I of this proposal, we will conduct studies to demonstrate the feasibility of commercializing this research based assay. The successful completion of this Phase I proposal will demonstrate the feasibility of producing an easy to use, marketable global test in the arena of clinical hemostasis testing that is sensitive to antithrombotic drugs, bleeding disorders and thrombotic pathologies. This assay will offer significant cost advantages over current technologies by potentially replacing the need to perform multiple assays to determine an individual's haemostatic risk potential.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government